Study Reviews Evidence Supporting Use of Cannabinoids to Treat ALS
March 1, 2017 - als
The journal Neural Regeneration Research has published a examination detailing a latest commentary in a use of cannabis-derived compounds to provide amyotrophic parallel sclerosis (ALS).
The review, “Can cannabinoids be a intensity healing apparatus in amyotrophic parallel sclerosis?,” records that to date, a usually accessible therapy for ALS patients is riluzole, that controls neuronal signaling. However, this drug has singular healing value and usually tolerably increases presence — definition novel and some-more effective therapeutic options for ALS patients are still needed.
Cannabinoids, a bioactive compounds of Cannabis sativa, strive their activity by contracting to a CB1 and CB2 receptors.
The cannabinoid complement seems to be concerned in a pathology of ALS. Indeed, a spinal cord of ALS patients has been shown to benefaction engine neuron repairs triggered by defence system’s cells (microglia and macrophages) that demonstrate increasing levels of a CB2 cannabinoid receptor.
“So all these information uncover how modifying CB2-mediated processes could change ALS course and how many a endocannabinoid complement is potentially concerned in shortening neuroinflammation, excitotoxicity and oxidative dungeon damage,” researchers wrote.
Previous studies have shown that cannabinoids have antioxidant, anti-inflammatory and neuroprotective actions in animal models of ALS. Indeed, cannabinoids can delay illness course and lengthen presence in these animals. However, usually a few studies have investigated a outcome of cannabinoids in tellurian patients, that creates it formidable to interpret a results.
“According to a singular observational investigate of patients with ALS, usually a 10 percent who certified immoderate cannabis revealed assuage service of several symptoms, including ardour loss, depression, pain and drooling,” researchers wrote. “In addition, spasticity is also a major problem for ALS patients, that reported that cannabis can subjectively urge spasticity.”
They added: “There is a current motive to introduce a use of cannabinoid compounds in a pharmacological government of ALS patients. Cannabinoids indeed are means to check ALS course and lengthen survival. However, many of a studies that investigated a neuroprotective intensity of these compounds in ALS were achieved in animal models, since a few clinical trials that investigated cannabinoids-based medicines were focused usually on a alleviation of ALS-related symptoms, not on a control of illness progression.”
The researchers pronounced they wish scientists will keep studying how cannabinoids might be of healing use for ALS patients.
Print This Page